A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

Publication Type:

Journal Article

Authors:

Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A; del Rio, E; Baiget, M

Source:

British journal of cancer, Volume 105, Issue 1, p.53-7 (2011)

URL:

http://dx.doi.org/10.1038/bjc.2011.206

Abstract:

Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC). Irinotecan is converted into 7-ethyl-10-hydroxycamptothecin (SN-38) by a carboxylsterase and metabolised through uridine diphosphate glucuronosyl transferase (UGT1A1). The UGT1A1*28 allele has been associated with the risk of developing severe toxicities. The present trial was designed to define the maximum tolerated dose according to UGT1A1 genotype. This report focuses on the results of tolerance to different escalated doses of FOLFIRI first-line of chemotherapy.

Pubmed ID: 21654688